CD276 (B7-H3) Monoclonal Antibody (7-517), APC, eBioscience™, Invitrogen™

Description

• Description: This 7-517 monoclonal antibody reacts with human CD276, which is also known as B7-H3
• This type I transmembrane protein is expressed on immature and mature dendritic cells but not monocytes, granulocytes, or resting lymphocytes
• Moreover, CD276 is expressed on non-hematopoietic cells such as osteoblasts, fibroblasts, and epithelial cells
• However, CD276 expression can be induced on dendritic cells, monocytes, T, B, and NK cells
• This co-stimulatory molecule binds activated T cells, leading to cell proliferation and IFN-gamma production
• Applications Reported: This 7-517 antibody has been reported for use in flow cytometric analysis
• Applications Tested: This 7-517 antibody has been pre-titrated and tested by flow cytometric analysis of normal human monocyte-derived dendritic cells
• This can be used at 5 μL (0.125 μg) per test
• A test is defined as the amount (μg) of antibody that will stain a cell sample in a final volume of 100 μL
• Cell number should be determined empirically but can range from 10^5 to 10^8 cells/test
• Excitation: 633-647 nm; Emission: 660 nm; Laser: Red Laser
• Filtration: 0.2 μm post-manufacturing filtered
• CD276 is a member of the B7 family of co-stimulatory molecules also known as B7-H3
• CD276 is a type I transmembrane protein that induces the proliferation of CD4+ and CD8+ T cells, enhances the generation of cytotoxic T cells and selectively stimulates the production of interferon gamma
• Expression of CD276 can be induced on dendritic cells and monocytes by inflammatory cytokines, and is also widely expressed in peripheral tissues including the heart, kidney, testis and colon
• In humans, CD276 exists as two isoforms which result from gene duplication and differential splicing
• CD276 is reported to have therapeutic potential for the regulation of cell-mediated immune responses to cancer, particularly in conjunction with anti-angiogenic therapy.